Laadem, Abderrahmane

A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.

Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., et al. (2020) · New England Journal of Medicine

Hemoglobinopathies and Related DisordersBlood transfusion and management

Cited by 332

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Platzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology

Acute Myeloid Leukemia ResearchErythropoietin and Anemia Treatment

Cited by 292

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Piga, A., Perrotta, S., Gamberini, M. R., Voskaridou, E., Melpignano, A., Filosa, A., Caruso, V., Pietrangelo, A., Longo, F., Tartaglione, I., et al. (2019) · Blood

Hemoglobinopathies and Related DisordersIron Metabolism and Disorders

Cited by 119

453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

Doi, T., Patel, M., Falchook, G. S., Koyama, T., Friedman, C. F., Piha-Paul, S., Gutierrez, M. E., Abdul-Karim, R., Awad, M., Adkins, D. R., et al. (2022) · Annals of Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 44